PubMed Health⌕ Search

Biomedical subjects

D L Camenga

Publications and source records attributed to D L Camenga.

10 recordsLinked to original sources

Preliminary trial of 3,4-diaminopyridine in patients with multiple sclerosis.

Ten patients with multiple sclerosis (MS) were enrolled in a preliminary trial of the potassium channel blocker, 3,4-diaminopyridine, to evaluate drug toxicity and pharmacokinetics. The patients were treated with oral 3,4-diaminopyridine, first with increasing single doses up to 100 mg and then with divided dosage for up to 3 weeks. Paresthesias were reported by all patients and abdominal pain was dose limiting in 6 patients. 3,4-Diaminopyridine levels and half-life varied widely from patient to patient. Cerebrospinal fluid levels of 3,4-diaminopyridine were about 10% of those in serum. Neither seizures nor epileptiform changes on electroencephalographic examination occurred. Small reversible improvements in specific neurological deficits were seen on examination in all patients and reversible improvement in visual evoked response latencies were found in 2 patients. These results suggest that further study of 3,4-diaminopyridine in patients with MS is warranted.

4-Aminopyridine↗

[Herpes simplex 1 virus encephalitis. Early diagnosis with magnetic tomography (MT)].

Early institution of therapy with acyclovir is essential for the successful outcome in herpes simplex encephalitis. Brain biopsy remains the only conclusive means of establishing the diagnosis, but many fear possible biopsy complications. Thus, therapy is often instituted when the diagnosis is clinically suspected, even though cerebral computed tomography and other diagnostic studies may be inconclusive. Nuclear magnetic resonance imaging (MRI) has proven to be a sensitive tool for diagnosing presumptive herpes simplex encephalitis, and this case presentation demonstrates the superiority of cerebral MRI over computerized tomography for detecting early temporal lobe changes consistent with acute herpes simplex encephalitis.

Adolescent↗

The placebo effect during a double blind trial of recombinant alpha 2 interferon in multiple sclerosis patients: immunological and clinical findings.

A double-blind, placebo controlled trial of recombinant alpha 2 interferon in relapsing/remitting multiple sclerosis patients was performed to assess the clinical and immunological responses to treatment. This study demonstrated that natural killer (NK) cell activity, known to be enhanced by interferon (IFN) treatment, increased during the first week of treatment in both the IFN and placebo treatment groups. After the first week of treatment NK cell activity returned to baseline levels in both groups, and subsequently declined in the IFN treatment group. Patients in both groups improved clinically, as evidenced by a reduction in the exacerbation rate. Furthermore, a similar incidence of adverse reactions to treatment were reported by both groups. The mechanism underlying the response to placebo is not known. However, it is unlikely that the long term clinical improvement (one year) in either group is related to the transient increase in NK cell activity.

Adult↗

Systemic recombinant alpha-2 interferon therapy in relapsing multiple sclerosis.

This report describes the first use of recombinant-DNA-produced human interferon in patients with multiple sclerosis (MS). Ninety-eight patients who were clinically definite for MS with two or more documented exacerbations during the preceding two years were admitted to this placebo-controlled double-blind randomized trial. Although both groups were similar, placebo patients had later MS onset. Patients injected themselves with 2 X 10(6) IU of alpha-2 interferon or placebo three times each week for up to 52 weeks. This dose of interferon was well tolerated in that side effects were minimal. During the trial, the exacerbation rate was sharply reduced in both groups. In the three-month follow-up period after stopping treatment, more patients who were receiving interferon than placebo became worse neurologically. More patients who were receiving interferon than placebo changed from exacerbating MS to progressive MS during the trial. Thus, no clear therapeutic benefit of alpha-2 interferon for MS was detected.

Adult↗

Recurrent herpes zoster encephalitis. A complication of systemic lupus erythematosus.

A middle-aged woman had five discrete episodes of herpes zoster. The first attack consisted of uncomplicated herpes zoster ophthalmicus. The subsequent four episodes involved thoracic, cervical, and finally sacral dermatomes and were complicated by myelitis or encephalomyelitis. During the most recent attack, while she was receiving corticosteroids, varicella-zoster virus was cultured from the CSF. In addition, the patient had strong evidence of systemic lupus erythematosus, with a history of Raynaud's phenomenon, migratory arthralgia, and unexplained anemia before the first attack of zoster with subsequent development of a positive lupus cell preparation and elevated antinuclear antibody levels.

Cerebrospinal Fluid↗

Anticonvulsant prolongation of survival in adult murine lymphocytic choriomeningitis. I. Drug treatment and virologic studies.

Lymphocytic choriomeningitis virus-induced central nervous system disease is characterized by death during a seizure approximately seven days after intracerebral inoculation. This process is mediated by thymus dependent lymphocytes, sensitized against viral antigens. Various forms of immunosuppressive treatment prevent the seizure death and produce persistently infected survivors. In this study, anticonvulsant treatment (particularly diazepam treatment) of LCM virus infected mice prolonged survival without affecting viral replication, or suppressing immune responsiveness. This prolongation of life did not lead to a reversal of pathologic processes and there were no survivors. However, anticonvulsant treatment permitted study of more advanced stages of the choriomeningitis than has previously been possible.

Animals↗

Anticonvulsant prolongation of survival in adult murine lymphocytic choriomeningitis. II. Ultrastructural observations of pathogenetic events.

Because previous ultrastructural studies of murine lymphocytic choriomeningitis (LCM) had revealed only mononuclear cell infiltration with no cytopathology of target cells in the choroid plexus, ependyma, and leptomeninges, diazepam treatment was used to prolong survival for characterization of late pathogenetic events. Mice which were treated with diazepam and sacrificed 8, 9, and 10 days after intracerebral inoculation with LCM virus showed an increasing amount of inflammatory infiltration into choroid plexuses, leptomeninges, Virchow-Robin spaces, and ependyma. Mononuclear cells, lymphocytes, and polymorphonuclear (PMN) leukocytes increased in number as compared with terminally infected mice sacrificed 7 days after inoculation. Ultrastructurally, choroidal epithelial cells showed cytopathological changes varying from dilated endoplasmic reticulum through necrosis. Greater numbers of PMN leukocytes, macrophages, and activated macrophages and fewer undifferentiated mononuclear cells were seen in choroid plexuses of the drug-treated survivors. Virions and larger, more numerous arenavirus inclusions were present in choroid plexus and ependyma. Ultrastructurally the leptomeningitis was characterized by large numbers of activated macrophages. Choroidal epithelial necrosis appears to be the in vivo correlate of T-cell-mediated cytotoxicity in vitro.

Animals↗

An immunopathologic component in experimental togavirus encephalitis.

The effects of immune manipulation upon survival and histopathology in two experimental group B togavirus encephalitides were studied in inbred mice. The median survival time 8 days after intracerebral injection of Langat virus increased to 10 days with an immunosuppressive course of cyclophosphamide, with concomitant reduction in the inflammatory response. Adoptive immunization with immune lymphoid cells or serum also tended to prolong Langat virus survival while increasing inflammation. Survival following intracerebral West Nile virus (7 days) was unaffected by immunosuppression or adoptive transfer, although suppression was associated with less severe CNS lesions, and immune serum with less necrosis. These findings indicate that the immune response may be both protective and pathology-inducing in some togarvirus encephalitides. The differences in host response to these two related agents suggest caution in generalizing about the role of the immune response in viral infections.

Animals↗